iCoat Medical is developing the pharmaceutical treatment iCM012, designed to reduce ischemia-reperfusion injury during organ transplantation. This technology aims to improve transplant outcomes by addressing the cellular damage that occurs when blood supply returns to the organ after a period of ischemia.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Organ transplantation faces challenges related to ischemia-reperfusion injury (IRI), which occurs when blood supply is restored to the organ after a period of oxygen deprivation. This injury can lead to cellular damage and negatively impact transplant outcomes.
Solution
iCoat Medical is developing iCM012, a pharmaceutical treatment designed to mitigate ischemia-reperfusion injury during organ transplantation. iCM012 aims to improve transplant success rates by addressing the cellular damage associated with the restoration of blood flow to the transplanted organ. The treatment is the result of over 25 years of research and development in collaboration with leading academic institutions.
Target Audience
The primary target audience includes transplant surgeons, hospitals, and patients undergoing organ transplantation.
Features
- Pharmaceutical treatment targeting ischemia-reperfusion injury.
- Designed to reduce cellular damage during organ transplantation.
- Developed in collaboration with leading academic institutions.